Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
Emanuele de Rinaldis(Target (United States)), Andrew Tutt(Institute of Cancer Research), Patrycja Gazińska(London Cancer), Lars Holmberg(Guy's Hospital), Brian Burford(Guy's Hospital), Anita Grigoriadis(London Cancer), Cheryl Gillett(King's College London), Grazyna Fedorowicz(Veracyte (United States)), Zora Modrušan(Unknown), Anca Mera(Guy's and St Thomas' NHS Foundation Trust), Pierfrancesco Marra(King's College London), Sarah E. Pinder(St Thomas' Hospital), David Dornan
Cited by 87
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k